Antisense Oligonucleotides Market - By Type , By Application , By Route of Administration , By End Use Industry , By Geography Analysis - Global Opportunity Analysis & Industry Forecast, 2025-2031

Antisense Oligonucleotides Market Overview

The Antisense Oligonucleotides Market is estimated to reach $5.3 billion by 2031, growing at a CAGR of 6.6% from 2025 to 2031. The Antisense Oligonucleotides Market is primarily driven due to the increasing cases of neurological diseases, progressing Antisense Oligonucleotides innovations and ASO research, personalized medicine and targeted therapeutics. The Next Generation Antisense Oligonucleotides modifications and growing investments and partnerships for better progression in the product are some of the key trends influencing the Antisense Oligonucleotides Market. In November 2024, Trace Neuroscience invested $101 billion in funding to develop a treatment for ALS after its launch in the market. The fundraising, led by Third Rock Ventures with participation from Atlas Venture, GV, and RA Capital Management aims to restore a key protein, UNC13A, which is often low or absent in ALS patients and has been linked to the progression of the disease (restore malfunctioning neurons). 

Antisense Oligonucleotides Market - Report Coverage:

The report: “Antisense Oligonucleotides Market – Forecast (2025-2031)”, by IndustryARC, covers an in-depth analysis of the following segments of the Antisense Oligonucleotides Industry.

Key Takeaways:

North America is the Largest

North America holds the majority market share in 2024 in the market due to strong R&D investments, regulatory approvals, and advanced healthcare infrastructure. The region dominates ASO commercialization, particularly for neurological disorders. In November 2024, the Mayo Foundation reported that 6.9 billion U.S. adults (65+) have Alzheimer’s disease, with over 70% aged 75+.  The National Institute of Health estimates that 14% of Americans have non-communicable neurological diseases, which is expected to triple the number by 2050, published by the World Federation of Neurology. With the widespread of the growing disease and strong government support, North America remains the largest in the Antisense Oligonucleotides Market.

Neurodegenerative Diseases is the Largest

Neurodegenerative Diseases hold the largest share in the market. This is due to the growing need for treatments like Spinal Muscular Atrophy (SMA), and Huntington’s disease. According to the Cleveland Clinic, over 50 billion people worldwide are affected by Neurodegenerative conditions, which are more common in people over 65. Also, The World Health Organization (WHO) estimates the 65+ population will double in 30 years, leading to a sharp rise in cases. Additionally, Johns Hopkins Medicine reports that 15,000+ Americans have Huntington’s disease, with many more at risk. As these diseases increase, Antisense Oligonucleotides therapies are becoming a key approach to treatment, further increasing the market’s growth.

Intravenous Administration is the Largest

Intravenous Administration holds the largest share in the market in 2024. Intravenous (IV) administration stands out in delivering therapeutics directly into the bloodstream, ensuring high bioavailability for treating genetic disorders, cancers, and neurological conditions. According to Merck & Co. in November 2024, IV (Intravenous) administration allows precise dosing and controlled distribution, making it ideal for irritating solutions that could damage tissues via other routes. In 2023, the National Institutes of Health reported that Antisense Oligonucleotides (ASOs) comprised 16% of the 55 new chemical entities approved by the FDA, which is an increase from 14% in 2022. Among these, IV (Intravenous) administration remained a leading choice for systemic therapies. 

Advancing Antisense Oligonucleotide (ASO) Innovations & Research

The Antisense Oligonucleotides (ASO) market is growing rapidly, driven by advancements in genetic medicine and ongoing research. For instance, a study by the National Library of Medicine in August 2024 states that, RNA therapeutics have emerged as a groundbreaking line, enabling new treatment strategies such as RNA interference (RNAi) and ASOs. The discovery of RNAi has transformed gene regulation by making previously undruggable targets accessible for treatment. Additionally, in January 2025, the N-Lorem Foundation partnered with Gondolabio to accelerate ASO-based therapies for nano-rare diseases, offering hope for patients with extremely rare genetic disorders. These developments highlight the growing potential of ASOs in the market benefitting people and the market.

For more details on this report - Request for Sample 

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the Antisense Oligonucleotides Market. The top 10 companies in this industry are listed below:

1. Alnylam Pharmaceuticals
2. Isis Pharmaceuticals
3. Geron Corp
4.  Biogen
5. NS Pharma, Inc
6. Jazz Pharmaceuticals
7. Swedish Orphan Biovitrum AB
8. Sarepta Therapeutics
9. Ionis Pharmaceuticals
10. Novo Nordisk A/S

Scope of the Report: 

For more Lifesciences and Healthcare Market reports, please click here